Efficacy and safety of three ophthalmic inserts for topical anaesthesia of the cornea. An exploratory comparative dose‐ranging, double‐blind, randomized trial in healthy volunteers

Mahé, Isabelle; Mouly, Stéphane; Jarrin, I.; Otéro, Jacqueline; Tavera, Catherine; Simoneau, Guy G.; Tillet, Yves; Conti, Robert; Meski, Saïd El; Gaudric, Alain; Bergmann, Jean‐François

doi:10.1111/j.1365-2125.2004.02245.x

Cited by 6 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings suggest that hyaluronan, if mixed with bupivacaine, may not affect bupivacaine's anesthetic function. It has been reported in animal [ 17 ] and human studies [ 18 ] that the duration of sensory nerve blockade from bupivacaine is prolonged by addition of hyaluronan. Hassan et al described this extended action of the local anesthetic, but they did not determine the exact mechanism.…”

Section: Discussionmentioning

confidence: 99%

Hyaluronan Does Not Affect Bupivacaine’s Inhibitory Action on Voltage-Gated Potassium Channel Activities in Bovine Articular Chondrocytes

Hester

Yang²,

Wang³

et al. 2012

Advances in Orthopedics

View full text Add to dashboard Cite

Objectives. The objective of this paper is to determine if hyaluronan affects bupivacaine's anesthetic function. Methods. Whole cell patch clamp recordings were performed on bovine articular chondrocytes cultured in 60 mm dishes. The chondrocytes were treated with phosphate-buffered saline (control group), 7.5 mg/mL hyaluronan (Orthovisc), 0.25% bupivacaine, or a mixture of 7.5 mg/mL hyaluronan and 0.25% bupivacaine. Outward currents were elicited by step depolarization from −90 mV to 150 mV with 5 mV increments and holding for 200 ms. Results. The amplitude of outward currents elicited at 150 mV was 607.1 ± 135.4 pA (mean ± standard error) in the chondrocytes treated with phosphate buffered saline, 550.0 ± 194.9 pA in the chondrocytes treated with hyaluronan, 18.4 ± 8.3 pA in the chondrocytes treated with bupivacaine, and 12.8 ± 2.6 pA in the chondrocytes treated with a mixture of hyaluronan and bupivacaine. Conclusion. Hyaluronan does not affect bupivacaine's inhibitory action on the potassium channel activities in bovine articular chondrocytes. This finding suggests that intra-articular injection of a mixture of hyaluronan and bupivacaine may not affect the anesthetic effects of bupivacaine.

show abstract

Section: Discussionmentioning

confidence: 99%

Hyaluronan Does Not Affect Bupivacaine’s Inhibitory Action on Voltage-Gated Potassium Channel Activities in Bovine Articular Chondrocytes

Hester

Yang²,

Wang³

et al. 2012

Advances in Orthopedics

View full text Add to dashboard Cite

show abstract

“…These include the New Ophthalmic Delivery System (NODS), patented by Smith & Nephew in the mid 1980s but subsequently withdrawn from the market, and Bioadhesive Ophthalmic Drug Insert (BODI ® ) [43]. As well as providing drugs for treatment of a disease, soluble inserts have been investigated to provide anesthesia and corneal hydration during cataract surgery [44]. Hydration by soluble inserts may also help reduce the symptoms of dry eye.…”

Section: Nonimplantable Devicesmentioning

confidence: 99%

Drug delivery systems for the eye

Kearns

Williams

2009

Expert Review of Medical Devices

View full text Add to dashboard Cite

Topical and systemic administration of drugs to the eye is highly inefficient and there is a need for controlled, sustained release, particularly for conditions that affect the posterior segment. Various nonimplantable and implantable drug delivery devices have been developed. Colloidal carriers may allow targeted drug delivery and afford protection to substances that are sensitive to degradation, particularly RNA/DNA-based treatments. Gene therapy and cell transplantation are also starting to emerge as alternatives to conventional pharmacological treatment. There is the potential to use existing ocular devices to deliver drugs. In order to exploit this opportunity, modifications to drugs and devices, along with clarification of the appropriate drug dose, must be undertaken. This review will describe some of the treatment options for ocular disease and barriers to drug delivery, discuss the design of existing drug delivery systems and highlight some of the research into combining drug delivery with existing ocular medical devices.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2005

Pharmacoepidem. Drug Safe.

View full text Add to dashboard Cite

Efficacy and safety of three ophthalmic inserts for topical anaesthesia of the cornea. An exploratory comparative dose‐ranging, double‐blind, randomized trial in healthy volunteers

Abstract: BackgroundCataract surgery requires prolonged anaesthesia, concomitant with permanent hydration and lubrication of the cornea, in order to provide a clear view of the operation area.

Cited by 6 publications

References 10 publications

Hyaluronan Does Not Affect Bupivacaine’s Inhibitory Action on Voltage-Gated Potassium Channel Activities in Bovine Articular Chondrocytes

Hyaluronan Does Not Affect Bupivacaine’s Inhibitory Action on Voltage-Gated Potassium Channel Activities in Bovine Articular Chondrocytes

Drug delivery systems for the eye

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About